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Abstract 
Objectives: The UK National Institute for Health and Care Excellence (UK-
NICE) and European Society of Cardiology (ESC) guidelines advise 
natriuretic peptide (NP) assessment in patients presenting to primary care 
with symptoms possibly due to chronic heart failure (HF), to determine need 
for specialist involvement. This prospective service evaluation aimed to 
describe the diagnostic and prognostic utility of these guidelines. 
Methods: We prospectively collected clinical, echocardiography and 
outcomes data (minimum 5yrs) from all patients referred to the Leeds HF 
Service for 12m following the initiation of the NP-guideline-directed pathway. 
Results: Between May 1st 2012 and August 1st 2013, 1020 people with 
symptoms possibly due to HF attended either with a raised NT-pro-BNP or a 
previous myocardial infarction (MI) with an overall rate of LVSD of 33%. Of 
these, 991 satisfied the ESC criteria (NT-pro-BNP 125pg/mL) in whom the 
rate of LVSD was 32%, and 821 the UK-NICE criteria in whom the rate of 
LVSD was 49% in those with a previous MI, 25% in those with NT-pro-BNP 
concentration 400-2000pg/mL and 54% in those with NT-pro-BNP 
concentration of >2000pg/mL. An NT-pro-BNP concentration 125-400pg/mL 
had a 12% risk of LVSD. Specificity was poor in women >70yrs, who made up 
the largest proportion of attendees. Elevated NT-pro-BNP levels were 
associated with lower survival even in the absence of LVSD.  
Conclusion: In people referred through the ESC and UK-NICE guidelines, 
elevated NT-pro-BNP is a marker of increased mortality risk, but there is wide 
variation in specificity for LVSD. Age- and sex-adjusted criteria might improve 
performance. 
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Introduction 
Chronic heart failure due to left ventricular systolic dysfunction (LVSD) is a 
major cause of death and disability worldwide and a significant financial 
burden on global healthcare systems. Early diagnosis and institution of 
evidence-based medical therapies, in patients with chronic heart failure due to 
LVSD, has been shown to substantially reduce mortality[1] and unplanned 
hospitalisation,[2][3] the major contributor to the cost of chronic heart failure.[4] 
In primary care the accurate diagnosis of chronic heart failure remains 
difficult,[5][6] and the need to develop approaches to improve diagnosis is 
therefore important. 
 
Elevated B-type natriuretic peptide (BNP) concentrations are associated with 
an adverse prognosis in the general population,[7][8] and in people with [9][10][11] 
and without [12][13][14] LVSD and in heart failure, a reduction in NP 
concentrations with treatment is associated with an improvement in 
prognosis.[15] A series of screening studies in higher risk people have 
demonstrated that those with elevated BNP levels have a higher rate of 
LVSD.[7][16][17][18][19] Since 2008 and 2010 respectively, the European Society of 
Cardiology (ESC) and United Kingdom (UK) National Institute of Health and 
Care Excellence (UK-NICE) guidelines [20][21] have advocated measurement of 
serum concentrations of natriuretic peptides (NP), specifically BNP or NT-pro-
BNP, to aid in the clinical assessment of people presenting in primary care 
with symptoms possibly due to chronic heart failure. The guidelines differ in 
their cut-off values for NT-pro-BNP above which referral should be considered 
(ESC: 125pg/mL [22] and UK: >400pg/mL). The UK guidelines (but not those 
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from the ESC) suggest that a measurement of BNP is unnecessary in people 
with a history of myocardial infarction and also suggest that an NT-pro-BNP 
level >2000pg/mL should trigger a more urgent referral. The ESC guidelines 
were updated in 2016 and the UK-NICE guidelines have been updated in 
2018, but the cut-offs for referral are unchanged.[23] 
 
However, despite widespread adoption of BNP measurement as a diagnostic 
and prognostic marker in patients presenting with acute and chronic 
symptoms suggestive of heart failure, the positive and negative predictive 
values of BNP measurement within a management pathway based on the 
ESC or UK-NICE guidelines have, until now, remained unexplored. The aim of 
this prospective service evaluation was to define the diagnostic and 
prognostic value of the ESC and UK-NICE NP-based guidelines in unselected 
patients presenting to primary care with symptoms suggestive of chronic heart 
failure. 
 
Methods 
As part of a comprehensive a priori determined service evaluation of the ESC 
and UK-NICE guidelines referral algorithms we collected data on all patients 
referred to the Leeds Heart Failure Clinic following a raised NP test performed 
due to clinical suspicion of heart failure in primary care between 1st May 2012 
and 1st May 2013. Prior to the initiation of the NP-guided pathway, primary 
care teams had referred based upon clinical suspicion alone. In order to avoid 
IDOVHµQHJDWLYH¶WHVWVGXULQJWKHILUVW\HDUZHXVHGWKH(6&FXW-off of NT-pro-
BNP level SJP/DVWKHORZHUWKUHVKROGIRUUHIHUUDOZKLFKDOORZHGXVWR
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explore clinical features and outcomes when using both ESC and UK-NICE 
thresholds. The clinic covers a mostly urban and suburban catchment area of 
750,000 people, and the clinic provided the only route for further investigation 
during the period in question. 
 
Upon arrival at the clinic, demographic details, medical history, and medical 
therapy were recorded and patients underwent clinical assessment by 
specialist nurses. A history of previous myocardial infarction was confirmed 
from the patient-reported KLVWRU\ WKH JHQHUDO SUDFWLWLRQHUV¶ OHWWHUV and the 
hospital medical notes. Blood pressure was taken (right arm recumbent), 
electrocardiography and echocardiography performed, and patients were 
reviewed by one of two consultants with a specialist interest in CHF (KKW, 
MTK). At the end of their visit, a primary diagnosis was assigned to each 
patient. 
 
All NT-pro-BNP samples from practices referring to the Leeds Heart Failure 
Clinic were analysed in the biochemistry laboratory at Leeds Teaching 
Hospitals NHS Trust using the Immulite 2000 assay (Siemens Healthcare 
Diagnostics, Camberley, UK). The interbatch coefficient of variation was 8.9% 
at 350pg/mL and 5.9% at 4100pg/mL. Results were described numerically but 
included a commentary stating whether referral was recommended based 
upon the cut-off as described.  
 
Twelve lead electrocardiography 
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Standard 12-lead electrocardiographs (ECGs) recorded at 25mm/s were 
analysed by one of two cardiologists (MTK and KKW), who recorded rhythm 
(sinus rhythm or atrial fibrillation), heart rate and QRS duration. 
 
Echocardiography 
Two-dimensional echocardiography was performed according to American 
Society of Echocardiography recommendations by echocardiographers (JG, 
MP, JEL) without reference to NT-pro-BNP measurements. Left ventricular 
(LV) dimensions and ejection fractions were calculated according to 
recommended guidelines.[24] According to guidelines and the indications for 
therapy for heart failure in place at the time of data collection, LVSD was 
defined as an ejection fraction (EF) of <50%.[25]  
 
Mortality data 
Vital status data were collected using linked Hospital Episode Statistics and 
Office of National Statistics mortality data following S251 ethical approval 
(CAG 8-03(PR1)/2013). All patients had a minimum follow-up of 5 years.  
 
Statistical analysis 
All data items were recorded on case report forms and transferred to a 
bespoke database for statistical analysis. Patient characteristics were 
summarized according to the ESC NT-pro-BNP cut off (125pg/mL) or UK-
NICE pathway (previous MI, 400pg/mL-2000pg/mL, and >2000pg/mL).  
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The positive predictive value of the test was calculated as the number of true 
positive diagnoses of LVSD and therefore heart failure with reduced ejection 
fraction (HFrEF) divided by the number of patients attending clinic, separately 
by guideline category, after positive test result. 
 
Although neither guideline includes an adjustment for age or sex, other 
datasets suggest that these variables have an influence on NT-pro-BNP 
concentration.[26][27] We therefore also undertook an exploratory analysis to 
examine the performance of NT-pro-BNP as a diagnostic tool in subgroups 
GLYLGHGE\DJHDQG, sex (male versus female) and the presence of 
atrial fibrillation (AF), (yes or no) for both ESC and UK-NICE cohorts using 
Chi-squared analysis to explore differences between NT-pro-BNP category, 
age, sex and the presence of AF and renal dysfunction as covariates for the 
presence of LVSD. 
 
Survival analyses by guideline and category were performed to the censor 
date of 20th May 2018 and presented using Kaplan-Meier curves. Differences 
in survival between cohorts, categories of patients, and between those with 
and without LVSD, were analysed by log-rank survival tests.  
 
Analysis was performed using Staview 5.0, SAS Institute, USA. All statistical 
tests were two-sided and GHVFULEHGDV µVLJQLILFDQW¶ LIS. Throughout the 
present report, our methodology and results are reported according to the 
STROBE guidelines for observational studies.[28] 
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Results 
1020 adults with symptoms possibly due to heart failure were referred. The 
referral pathway for most was as a result of an elevated NT-pro-BNP, 
although 156 were referred on the background of previous myocardial 
infarction of whom 29 did not undergo an NT-pro-BNP measurement. 
 
Demographic data, medical history, symptomatic status and the results of 
investigations are shown in Table 1, divided by groups according to the 
guideline-directed criteria. A large proportion of patients (900/1020; 88%), 
were >70 years of age. More than 60% in each cohort self-reported symptom 
levels at New York Heart Association classes I or II. Overall, 49% and 55% 
were already taking a beta-blocker or RAAS antagonist (Table1).  
 
Diagnostic outcomes 
Overall, 334/1020 (33%) had evidence of LVSD confirming a diagnosis of 
HFrEF, although the proportion varied across the criteria.  
 
European Society of Cardiology criteria 
In this analysis we excluded patients referred via the MI pathway without an 
NT-pro-BNP level (n=29). This left 991 patients that fulfilled the ESC criteria 
for consideration of referral for echocardiography (NT-pro-BNP 
125pg/mL),[20] of whom 89% (878/991) were >70 years of age and 319/991 
(32%) had LVSD (Table 1). 
 
United Kingdom ± NICE criteria 
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Table 1 also shows the clinical and imaging variables for the cohort divided by 
the categories in the UK-NICE guidance. We excluded those with a previous 
MI from the UK-NICE NT-pro-BNP categories.  
 
The cohort with a previous MI (n=156) had a male preponderance, and most 
(136/156 (87%)) were >70years of age. Of these, 49% had evidence of LVSD 
on echocardiogram.  
 
Patients referred with an intermediate NT-pro-BNP level (400-2000pg/mL) 
had a female preponderance and most (395/436; 91%) were >70 years of 
age. In this cohort, 110/436 (25%) had evidence of LVSD. Patients referred 
ZLWK D µKLJK¶ 17-pro-BNP level according to the UK-NICE criteria 
(>2000pg/mL) were not older than those in the intermediate group (212/229; 
93% >70years; p=0.39) but did have a higher rate of LVSD than those in the 
intermediate group (123/229; 54%; p<0.0001).  
 
Overall, an NT-pro-BNP >400pg/mL was associated with LVSD in 233/665 
(35%) of patients without a previous MI. Therefore, whilst the positive 
predictive value of 400pg/mL is better than the ESC level of 125pg/mL, in our 
population we would have missed 24 cases of LVSD in 199 people (12%) 
without a previous MI. 
 
The influence of age, sex, renal dysfunction and atrial fibrillation on diagnostic 
outcomes 
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Neither the ESC nor UK-NICE guidelines include age or sex in their criteria. 
We found variable evidence of heterogeneity in the positive predictive value of 
a raised NT-pro-BNP by age and sex (Figures 1a and b). Specifically, in those 
with an NT-pro-BNP125pg/mL, 38% (n=43/113) of patients <70 years 
compared with 32% (n=276/878 LQ WKRVH  \HDUV KDG /96' ȋ2=2.00; 
p=0.15). In the UK-NICE 4000-2000pg/mL cohort the positive predictive value 
LQWKH\RXQJHUDQGROGHUSDWLHQWVZHUHDQGUHVSHFWLYHO\ȋ2 = 6.32; 
p=0.012) and in the >2000pg/mL cohort, younger patients were also more 
OLNHO\ WR KDYH /96' WKDQ WKRVH  \HDUV  Y  ȋ2=8.80; p=0.003). 
Using the ESC criteria overall 44% (n=187/426) of men compared with 24% 
(n=132/565) of women had LVSD. These differences in performance were 
also present at both UK-NICE categories with men more likely to have LVSD 
at both NT-pro-BNP categories (400-2000pg/mL:  Y  ȋ2=11.78; 
p=0.0006, and 2000pg/mLYȋ2=8.65; p=0.0033). Whilst only 19% 
of elderly women with a NT-pro-BNP 400-2000pg/mL had LVSD, they 
represented 40% of all referred patients (Figures 1a and b). 
 
For patients satisfying the ESC guidelines, 31% of patients in sinus rhythm 
had LVSD (217/703) compared with 35% of those in atrial fibrillation 
(102/288). Regarding UK-NICE groups, in the µintermediate¶ group, 27% of 
people in sinus rhythm had LVSD (80/300), compared with 23% of people in 
atrial fibrillation (30/130); in the µhigh¶ group 59% of people in sinus rhythm 
had LVSD (66/112), compared with 49% of people in atrial fibrillation (57/117). 
None of these positive predictive values were statistically significant between 
groups with sinus rhythm and atrial fibrillation.  
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For patients satisfying the ESC guidelines, 31% of patients with an estimated 
glomerular filtration rate (eGFR) 60 had LVSD (204/656) compared with 34% 
of those with an eGFR<60 (114/331). Regarding UK-NICE groups, in the 
µintermediate¶ group, 27% of people with an eGFR 60 had LVSD (76/287), 
compared with 23% of people with an eGFR<60 (33/146); in the µhigh¶ group 
57% of people with an eGFR 60 had LVSD (68/120), compared with 51% of 
people with eGFR<60 (55/108). None of these positive predictive values were 
statistically significant between groups with preserved and impaired renal 
function. 
 
Prognostic outcomes 
We had vital status in all except 2 attendees to the censor date of 20th May 
2018 with a minimum of 5 years of follow-up (in total >6340 patient-years). 
Compared with patients with a µORZ¶ 17-pro-BNP concentration according to 
the UK-NICE guidelines, patients with both a µKLJK¶ NT-pro-BNP 
(>2000pg/mL) (HR 5.98, 95% CI 4.33-8.25) and those with an intermediate 
result (400-2000pg/mL) (HR 3.08, 95% CI 2.25-4.20) had a significantly 
higher mortality rate at 5 years (Figure 2). The overall 5 year survival rate of 
those with a µKLJK¶NT-pro-BNP level was 41.9 (95% CI 35.4-48.4) whilst the 
survival of the 125pg/mL group, at 60.8% (95% CI 57.9-63.7) was similar to 
that of the UK-NICE 400-2000pg/mL (intermediate) (61.8 (95% CI 57.3-66.3) 
DQGµ0,¶FRKRUWV (55.8, 95% CI 48.0-63.6). Although the absence of LVSD in 
those with elevated NT-pro-BNP levels according to the ESC criteria was an 
independent predictor of good outcome (HR 0.70, 95% CI 0.57-0.81) the 
presence of LVSD was not additive in any of the UK-NICE criteria (Figures 3a 
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and b). No patient with a previous MI and only 2 in the >2000pg/mL group 
died within the first 6 weeks after the referral or blood test. 
  
Discussion 
This is the first prospective study to report the diagnostic and prognostic value 
of two diagnostic pathways for possible heart failure that include natriuretic 
peptide (NP) measurement in primary care. We demonstrate in unselected 
consecutive patients referred from primary care with symptoms or signs 
possibly due to heart failure and a raised NT-pro-BNP that 32% and 35% of 
those investigated and referred according to the current ESC and UK-NICE 
guidelines will have LVSD. Importantly however, we also found that 12% of 
people with symptoms but an NT-pro-BNP level 125-400pg/mL have LVSD. 
 
Diagnosing chronic heart failure due to LVSD in primary care is difficult. 
Symptoms such as breathlessness and fatigue have poor specificity, while 
those such as orthopnoea and lung crepitations are rare and have low 
sensitivity.[5][29] Chest radiography is often also unhelpful.[30] Hence more 
refined approaches are required to improve the diagnosis of chronic heart 
failure in primary care, and pathways to achieve this form a central part of the 
UK-NICE and European Society of Cardiology guidelines for the diagnosis 
and management of chronic heart failure.[20][21] For almost a decade, these 
pathways have included an assessment of NP concentrations. In contrast to 
the US guidelines, which suggest that a measurement of NP can be helpful,[31] 
the ESC and UK-NICE guidelines describe cut-offs for NP above which 
referral is advised. 
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 Much of the historical work on the utility of NP testing in the diagnosis of 
chronic heart failure is based either on screening studies of people at higher 
risk of heart failure,[7][16][17][18][19] studies of acute destabilised heart failure[32] or 
acute breathlessness presenting to the emergency room.[33][34][35][36][37][38] The 
data describing the positive predictive value of NP for LVSD stem from 
modestly sized cohorts of people referred from primary care with sub-acute 
breathlessness in whom a test was done at the heart failure clinic following a 
referral based upon clinical suspicion.[39][40][41][42][43][44] Only one published 
study has described a pathway where the NP measurement was done in 
primary care at the clinic, but in this study, the protocol mandated referral for 
echocardiography in each subject limiting the usefulness of this work to clarify 
the utility or cost-effectiveness of the pathway in usual practice.[45] 
 
Despite widespread adoption of NP-based care pathways, we could find no 
data exploring the utility of NP testing performed in primary care, and 
specifically whether including the test in the clinical assessment of a 
symptomatic patient improves the specificity of a referral to a secondary care 
heart failure service for heart failure due to LVSD over clinical suspicion 
alone. In the studies described above, where referral was based upon clinical 
suspicion, the median prevalence of heart failure due to LVSD was 28% of 
attendees (range 23%-60%). Since the prevalence of attendees in our dataset 
with LVSD is similar, one interpretation of our dataset could be that adding the 
NP test to clinical suspicion may not improve the positive predictive value of a 
NT-pro-BNP test done in primary care for a diagnosis of LVSD, although the 
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denominator might be different. The REFER dataset mentioned above,[45] 
which mandated referral in people assessed with a NP test, found a low 
prevalence in their 304 attendees of whom only 13 had LVSD (LVEF <50%) 
with only 3 presenting with an LVEF <40%).[45] 
 
The UK-NICE guidelines also include a recommendation that patients with 
particularly high concentrations (NT-pro-BNP>2000pg/mL) and those with a 
prior MI should receive an urgent outpatient appointment (within two weeks). 
Our data demonstrate that around half of these patients will not have CHF 
due to LVSD, that around 70% have no signs or symptoms of clinical 
instability and by the time of clinic attendance a proportion will have no 
ongoing symptoms (NYHA class I).  
 
Although there are data suggesting that NP concentrations are influenced by 
age and sex,[46] neither ESC nor UK-NICE guidelines propose age-sex 
specific thresholds. Our data support previous work [27][47] suggesting that 
these variables influence the performance of NT-pro-BNP in identifying 
patients with heart failure due to LVSD. Although the test performed better in 
high risk groups, these patients made up a small proportion of referred 
patients. Specifically, only 19% of elderly women with a NT-pro-BNP 400-
2000pg/mL, which make up 40% of all referred patients, have LVSD. It is 
possible therefore that age and sex adjusted guidelines would improve 
specificity without affecting sensitivity of the test in primary care. 
 
Prognostic utility of a raised NP 
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Our unique dataset allow us to clarify clearly in a well characterised cohort of 
patients that a raised NT-pro-BNP is a marker of adverse prognosis even in 
people without LVSD as previously described.[14] Our data highlight that 
despite contemporary medical therapy coordinated by a secondary care clinic 
with a high rate of optimal doses,[48] the prognosis for consecutive, unselected 
elderly patients with HFrEF remains poor. 
 
Limitations of study 
Our dataset is highly relevant to day to day clinical practice as it assessed in 
an unbiased fashion all consecutive and unselected patients referred using 
the ESC and UK-NICE guidelines. Moreover, vital status to at least 5 years is 
also a significant strength of our report. There are however, some limitations 
that should be discussed. Our report describes a single centre experience so 
it would be useful to examine the utility of an NP-guided pathway in different 
settings. Our data suggest that an elevated NT-pro-BNP level is associated 
with a poor prognosis even in those without LVSD. Although we recorded 
images for future analyses, the assessment of diastolic function was not part 
of the a priori aims of this particular piece of work. We have therefore not 
addressed other causes of elevated NT concentrations including HFpEF in 
this manuscript as these form part of a separate project. Furthermore,  
although optimal medical and device therapy can reduce mortality and 
morbidity in patients with heart failure due to LVSD,[1] to our knowledge no 
therapy has yet been shown to improve prognosis in people with chronic heart 
failure without LVSD,[20] possibly limiting the benefit on prognosis of a 
diagnostic pathway for this group. Whilst it is true that many interventions 
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possibly of benefit to people without LVSD, for example dietary advice and 
diuretic therapy have not been formally tested they might nevertheless 
improve both symptoms and important outcomes such as mortality and 
hospitalisation rates. Furthermore, a raised NP level that stimulated a referral 
may lead to a diagnosis of other conditions such as atrial fibrillation for which 
earlier treatment might be beneficial. A formal assessment of an NP-guided 
pathway would be able to describe the benefits in people with and without 
LVSD.  
 
A further limitation of the observational cohort design of our service 
evaluation, is that we did not mandate referral of all patients undergoing the 
blood test, restricting our ability to comment on the negative predictive value 
of low NT-pro-BNP values in either pathway. However, our prospective use of 
the ESC guidelines for referral allows us to describe a 12% false negative rate 
in those with NT-pro-BNP levels between 125-400pg/mL.  
 
Conclusion 
In patients with suspected chronic heart failure referred using the ESC 
guidelines 32% had chronic heart failure secondary to LVSD whilst using 
2010 UK-NICE guidelines 35% had chronic heart failure secondary to LVSD 
but there was wide variation in specificity in subgroups with the test 
performing poorly in older women. Overall, these positive predictive value 
rates are similar to those historically seen in the literature following referral 
based upon clinical judgement alone. Furthermore, 12% of people with an NT-
pro-BNP between the ESC and 2010 UK-NICE guidelines have LVSD. Our 
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 Legends 
 
Figures 1a and b The performance of European Society of Cardiology 
(ESC) (panel a), and United Kingdom Institute for Health 
and Care Excellence (UK-NICE) NT-pro-BNP 
concentrations (panel b) to identify people with heart 
failure due to left ventricular systolic dysfunction, divided 
by age and sex 
 
Figure 2 All cause mortality of attendees by European Society of 
Cardiology (ESC) and United Kingdom Institute for Health 
and Care Excellence (UK-NICE) referral category 
 
Figures 3a and b All cause mortality of attendees by European Society of 
Cardiology (ESC) (panel a) and United Kingdom Institute 
for Health and Care Excellence (UK-NICE) (panel b) 
referral category by presence of left ventricular systolic 
dysfunction 
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Referral variables 
All patients 
(n=1020) 
ESC criteria 
(ш125pg/mL) 
(n=991) 
NICE criteria (n=821) 
Previous MI 
(n=156) 
400-2000pg/mL 
(n=436) 
>2000pg/mL 
(n=229) 
Age (years) 82 (10) 82 (10) 81 (10) 83 (9) 85 (9) 
Sex  male (%) 445 (44) 426 (43) 89 (57) 181 (42) 106 (46) 
 female (%) 575 (56) 565 (57) 67 (43) 255 (58) 123 (54) 
NT-pro-BNP (pg/mL) (median, IQR) 882 (1712) 891 (1712) 999 (1727) 813 (643) 3685 (4552) 
NYHA class I (%) 55/346 (16) 52/336 (15) 13/84 (15) 27/115 (23) 12/124 (10) 
 II (%) 185/346 (51) 171/336 (51) 44/84 (52) 59/115 (51) 74/124 (60) 
 III (%) 107/346 (30) 99/336 (29) 27/84 (32) 24/115 (21) 31/124 (25) 
 IV (%) 10/346 (3) 10/336 (3) 0/84 (0) 2/115 (2) 7/124 (6) 
Previous myocardial infarction (%) 156 (15) 127 (13) 156 (100) - - 
Hypertension (%) 578 (57) 563 (57) 72 (46) 259 (59) 136 (59) 
Previous stroke (%) 88 (9) 85 (9) 15 (9) 40 (10) 25 (11) 
Diabetes mellitus (%) 212 (21) 206 (21) 44 (28) 94 (22) 40 (17) 
Previous cardiac surgery (%) 74 (7) 69 (7) 28 (18) 30 (7) 9 (4) 
On examination      
HR (beats/min) 75 (17) 75 (17) 71 (17) 75 (16) 81 (20) 
Systolic blood pressure (mmHg) 141 (24) 141 (23) 136 (26) 142 (22) 137 (24) 
Diastolic blood pressure (mmHg) 74 (12) 74 (12) 72 (13) 73 (12) 74 (13) 
Weight (kg) 79 (20) 79 (20) 77 (18) 78 (20) 76 (19) 
Height (cm) 163 (10) 163 (10) 164 (10) 163 (11) 163 (10) 
Electrocardiogram      
Atrial fibrillation (%) 292 (29) 288 (29) 36 (23) 136 (31) 117 (51) 
QRS duration (ms) 100 (24) 99 (24) 102 (25) 98 (23) 108 (26) 
Echocardiogram      
LVEF <50% (%) 334 (33) 319 (32) 77 (49) 110 (25) 123 (54) 
LVEF (%) 50 (11) 50 (11) 44 (14) 52 (9) 44 (13) 
Baseline treatment      
Beta-blockers (%) 504 (49) 480 (48) 115 (74) 196 (45) 129 (56) 
RAAS inhibitors (%)  568 (55) 543 (55) 117 (75) 238 (55) 120 (52) 
MRA (%) 39 (4) 35 (4) 14 (9) 11 (3) 13 (6) 
Regular loop diuretic (%) 397 (39) 385 (39) 61 (39) 151 (35) 133 (58) 
Summary data are presented as means (SD) for continuous variables unless indicated, and as frequency (%) for categorical variables. 
ESC; European Society of Cardiology, NICE; National Institute for Health and Care Excellence, MI; myocardial infarction,  
NYHA; New York Heart Association, LVEF; left ventricular ejection fraction, RAAS; renin angiotensin aldosterone system. 
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Figure 1a ± Positive predictive value of the ESC guidelines 
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Figure 2 ± Survival by cohort defined by the ESC and UK-NICE guidelines
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Figure 3a ± Survival by ESC cohort and presence of left ventricular systolic dysfunction
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Figure 3b ± Survival by UK-NICE cohort and the presence of left ventricular systolic 
dysfunction
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